ATHX Athersys, Inc.

-0.01  -1%
Previous Close 1.45
Open 1.44
Price To book 5.53
Market Cap 160.30M
Shares 111,316,000
Volume 386,735
Short Ratio 3.64
Av. Daily Volume 1,379,870

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released mid April 2015. Endpoints not met. Phase 3 MASTERS-2 trial to be initiated under SPA in 2017.
Ischemic stroke
Phase 2 enrolment but reported May 2016 that enrolment is slower than expected
Acute myocardial infarction